Apoptotic killing of B-chronic lymphocytic leukemia tumor cells by allicin generated in situ using a rituximab-alliinase conjugate

Molecular Cancer Therapeutics

Volumn 4, Issue 2, 2005, Pages 325-331

  Arditti, Fabian D ^a   Rabinkov, Aharon ^a   Miron, Talia ^a   Reisner, Yair ^a   Berrebi, Alain ^b   Wilchek, Meir ^a   Mirelman, David ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b KAPLAN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALLICIN; ALLIIN; ANTIBODY CONJUGATE; CD20 ANTIGEN; RITUXIMAB; RITUXIMAB ALLIINASE CONJUGATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; B LYMPHOCYTE; CHIMERA; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MANTLE CELL LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBON-SULFUR LYASES; CHIMERA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOTOXINS; LEUKEMIA, B-CELL, CHRONIC; MICE; MICE, INBRED BALB C; SULFINIC ACIDS; TUMOR CELLS, CULTURED;

EID: 14844286972     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Stoll A, Seebeck E. Chemical investigations on alliin, the specific principle of garlic. Adv Enzymol 1951;11:377-400.
2. Agarwal KC. Therapeutic actions of garlic constituents. Med Res Rev 1996;16:111-24.
3. Koch HP, Lawson LD. The Science and therapeutic application of Allium sativum and related species. 2nd ed. Baltimore, MD: William and Wilkins; 1996.
4. Hirsch K, Danilenko M, Giat J, et al. Effect of purified allicin, the major ingredient of freshly crushed garlic, on cancer cell proliferation. Nutr Cancer 2000;38:245-54.
5. Patya M, Zahalka MA, Vanichkin A, et al. Allicin stimulates lymphocytes and elicits an antitumor effect: a possible role of p21 ras. Int Immunol 2004;16:275-81.
6. Cavallito C, Buck JS, Suter CM. Allicin, the antibacterial of Allium sativum: I. Determination of the chemical structure. J Am Chem Soc 1944;66:1952-4.
7. Rabinkov A, Miron T, Konstantinovski L, Wilchek M, Mirelman D, Weiner L. The mode of action of allicin: trapping of radicals and interaction with thiol containing proteins. Biochim Biophys Acta 1998;1379: 233-44.
8. Miron T, Rabinkov A, Mirelman D, Wilchek M, Weiner L. The mode of action of allicin: its ready permeability through phospholipid membranes may contribute to its biological activity. Biochim Biophys Acta 2000;1463:20-30.
9. Freeman F, Kodera Y. Garlic chemistry - stability of S (2-propenil) 2-propene-1-sulfinothioate (allicin) in blood, solvents, and simulated physiological fluids. J Agri Food Chem 1995;43:2332-8.
10. Iovino CS, Camacho LH. Acute myeloid leukemia: a classification and treatment update. Clin J Oncol Nurs 2003;7:535-40.
11. von Schilling C. Immunotherapy with anti-CD20 compounds. Semin Cancer Biol 2003;13:211-22.
12. Costello RT, Rey J, Fauriat C, Gastaut JA, Olive D. New approaches in the immunotherapy of haematological malignancies. Eur J Haematol 2003;70:333-45.
13. Cao TM, Coutre SE. T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H). Hematology 2003;8:1-6.
14. von Mehren M, Adams GP, Weiner LM. Monoclonal antibody therapy for cancer. Annu Rev Med 2003;54:343-69.
15. Miron T, Mironchik M, Mirelman D, Wilchek M, Rabinkov A. Inhibition of tumor growth by a novel approach: in situ allicin generation using targeted alliinase delivery. Mol Cancer Ther 2003;2:1295-301.
16. Stoll A, Seebeck E. Synthesis of natural alliin. Experientia 1950;6:330.
17. Tchernychev B, Rabinkov A, Miron T, Wilchek M. Natural antibodies against alliinase in human serum and polyclonal antibodies elicited in rabbit share the same immunogenic determinants. Immunol Lett 2000; 71:43-7.
18. Miron T, Rabinkov A, Mirelman D, Weiner L, Wilchek M. A spectrophotometric assay for allicin and alliinase (Alliin Iyase) activity: reaction of 2-nitro-5-thiobenzoate with thiosulfinates. Anal Biochem 1998;265:317-25.
19. Degani Y, Patchornik A. Cyanylation of sulfhydryl groups by 2-nitro-5-thiocyanobenzoic acid. High-yield modification and cleavage of peptides at cysteine residues. Biochemistry 1974;13:1-11.
20. Carlsson J, Drevin H, Axen R. Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio) propionate, a new heterobifunctional reagent. Biochem J 1978;173:723-37.
21. Rabinkov A, Wilchek M, Mirelman D. Alliinase (alliin Iyase) from garlic (Allium sativum) is glycosylated at ASN146 and forms a complex with a garlic mannose-specific lectin. Glycoconj J 1995;12:690-8.
22. Miron T, Shin I, Feigenblat G, et al. A spectrophotometric assay for allicin, alliin, and alliinase (alliin Iyase) with a chromogenic thiol: reaction of 4-mercaptopyridine with thiosulfinates. Anal Biochem 2002;307: 76-83.
23. Lubin I, Segall H, Marcus H, et al. Engraftment of human peripheral blood lymphocytes in normal strains of mice. Blood 1994;83:2368-81.
24. Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001;98: 1326-31.
25. Perz J, Topaly J, Fruehauf S, Hensel M, Ho AD. Level of CD 20 expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2002;43:149-51.
26. Lin TS, Lucas MS, Byrd JC. Rituximab in B-cell chronic lymphocytic leukemia. Semin Oncol 2003;30:483-92.
27. Shimoni A, Marcus H, Dekel B, et al. Autologous T cells control B-chronic lymphocytic leukemia tumor progression in human → mouse radiation chimera. Cancer Res 1999;59:5968-74.
28. Arditti FD, Greenberg R, Dekel B, et al. Human colon adenocarcinoma in the SCID/CB6 radiation chimera is susceptible to adoptive transfer of allogeneic human peripheral blood mononuclear cells. J Hematother Stem Cell Res 2002;11:883-93.
29. Dekel B, Burakova T, Arditti FD, et al. Human and porcine early kidney precursors as a new source for transplantation. Nat Med 2003;9:53-60.
30. Arditti F, Aviner S, Dekel B, et al. Eradication of B-CLL by autologous and allogeneic host non-reactive anti-third party CTLs. Blood [Epub ahead of print] 2004, Jul 6.
31. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000;96:2655-63.
32. Burger JA, Kipps TJ. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma 2002;43:461-6.
33. Bomstein Y, Yuklea M, Radnay J, et al. The antiapoptotic effects of blood constituents in patients with chronic lymphocytic leukemia. Eur J Haematol 2003;70:290-5.
34. Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000;51:634-41.
35. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002;29:2-9.
36. Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003;101:949-54.
37. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000;95:3900-8.
38. Treon SP, Mitsiades C, Mitsiades N, et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother 2001;24:263-71.
39. Dillon SR, Mancini M, Rosen A, Schlissel MS. Annexin V binds to viable B cells and colocalizes with a marker of lipid rafts upon B cell receptor activation. J Immunol 2000;164:1322-32.
40. Lee S, Park S, Oh JW, Yang CH. Natural inhibitors for protein prenyltransferase. Plant Med 1998;64:303-8.
41. Wu G, Fang YZ, Yang S, Lupton JR, Turner NO. Glutathione metabolism and its implications for health. J Nutr 2004;134:489-92.